Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity

Seo, Eoi Jong; Lee, Joo Yong

doi:10.1155/2018/2376240

Cited by 5 publications

(2 citation statements)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that temporal Zone II sparing laser photocoagulation combined with IVB could be a good choice for Type 1 ROP patients to achieve complete regression while minimizing peripheral field defects. [ 12 ] The mean birth weight of the infants in our study with APROP was 1340 g. This is in accordance with similar results shown in other studies done on bigger Asian babies. [ 13 ] However, the high number of APROP cases points toward a need for improved neonatal intensive care unit practices.…”

Section: Discussionsupporting

confidence: 92%

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity

Bhat,

Patil

2023

Oman J Ophthalmol

View full text Add to dashboard Cite

PURPOSE: The purpose is to determine the advantages and role of supplemental deferred retinal laser treatment following intravitreal bevacizumab (IVB) monotherapy in cases of severe retinopathy of prematurity (ROP) requiring treatment. MATERIALS AND METHODS: This is a retrospective study involving preterm infants diagnosed with treatment requiring ROP, treated initially with bevacizumab monotherapy who subsequently received deferred laser treatment during the study period from April 2019 to March 2021. Deferred laser treatment was done when recurrence of ROP or plus disease was noted or nonprogression of retinal vasculature was noted on two consecutive examinations over 2 weeks. The main outcomes measured were the ability of the treatment to prevent ROP progression or recurrence and anatomic outcome at the last follow-up visit. RESULTS: Twenty-three eyes of 14 neonates were treated with a deferred laser treatment following the initial intravitreal injection of Bevacizumab. The mean postmenstrual age at which IVB was given was 34 +6 ± 1 +3 weeks. The mean duration between IVB and retinal laser was 5 +3 ± 3 +4 weeks. The mean weight at the time of injection was 1317.8 ± 231.8 g. The mean weight of the infants at the time of the laser was 2050 ± 813.9 g. None of the eyes developed recurrence or adverse anatomical outcomes following laser till the last available follow-up. CONCLUSIONS: In our small number of subjects, blinding complications of ROP were prevented by using a deferred laser treatment protocol following initial bevacizumab therapy in treatment requiring ROP. It is better suited in cases where compliance for long-term follow-up after bevacizumab therapy cannot be ensured.

show abstract

Section: Discussionsupporting

confidence: 92%

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity

Bhat,

Patil

2023

Oman J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In their study, Seo et al found no neurodevelopmental delay in the IVB and laser combination therapy group in the long term [48].…”

Section: Discussionmentioning

confidence: 78%

Outcomes of near confluent laser versus combined less dense laser and bevacizumab treatment of prethreshold ROP Type 1 Zone 2: a randomized controlled trial

et al. 2022

View full text Add to dashboard Cite

Background To evaluate the results of near confluent laser therapy versus combined less dense laser and intra vitreal bevacizumab in treatment of infants with type 1 retinopathy of prematurity (ROP) in zone II. Methods This is a prospective double-blinded randomized clinical trial study. Infants with Type 1 ROP in Zone 2 were randomized into case and control groups. Conventional laser therapy was executed for control group and combination of IVB and laser treatment was employed for the case group. Results Eighty-six eyes from 43 infants were analyzed in this trial. The first group included 42 eyes from 21 infants receiving a combination of laser ablation and IVB. The second group contained 44 eyes from 22 infants who received only conventional laser therapy. The combined IVB and laser ablation group demonstrated the neovascularization regression (20 out of 21 infants) one week after the procedure. In the conventional laser therapy group, this regression was found in (12 out of 22 infants) within one week after laser therapy (P = 0.001). Plus disease regression was observed in 20 (20/21) of combined treatment group and 7 infants (7/22) of conventional laser treatment group after one week. Conclusion Combined less dense laser and bevacizumab treatment resulted in more rapid regression in comparison with the conventional laser treatment. Trial registration IRCT20201120049450N1, 27/12/2021.

show abstract

Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity

et al. 2022

View full text Add to dashboard Cite

Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity

Cited by 5 publications

References 26 publications

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity

Outcomes of near confluent laser versus combined less dense laser and bevacizumab treatment of prethreshold ROP Type 1 Zone 2: a randomized controlled trial

Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity

Contact Info

Product

Resources

About